Report from AGM
NeuroVive Pharmaceutical AB (publ) held its Annual General Meeting (AGM) today, 9 May 2014. A summary of the resolutions follows. All decisions received the required majorities.
Press releases
NeuroVive presents medical breakthrough in cellular energy regulation
NeuroVive, a leading mitochondrial medicine company, is presenting a breakthrough in the company's work on energy regulation at the cellular level. Based on the UK company Selcia Ltd's medical chemist ...
Increased individual ownership through share exchange from Maas Biolab, LLC
One of NeuroVive's largest shareholders, Maas Biolab, LLC is reducing its ownership by 359,304 shares through a share exchange with its Swedish and US shareholders. This share exchange involves Maas B ...
NeuroVive presents significant hepatitis B data for its drug candidate NVP018
NeuroVive's anti-viral preclinical program, with compound designated NVP018, has generated significant data indicating that NVP018 has the potential to become an effective alternative or addition to c ...
NeuroVive Pharmaceutical and A1M Pharma initiate research collaboration
NeuroVive Pharmaceutical AB (publ) and A1M Pharma AB (publ) have announced that the two companies are initiating a research collaboration in mitochondrial medicine. The partnership is governed by a co ...
NeuroVive starts collaboration to evaluate IPO of subsidiary in Taiwan
NeuroVive Pharmaceutical AB (publ), a leading mitochondrial medicine company, is reporting that the company's subsidiary NeuroVive Pharmaceutical Asia Ltd., whose registered office is in Hong Kong, ha ...
NeuroVive treats final patient in European phase III trial on CicloMulsion®
NeuroVive Pharmaceutical AB (publ), a leading mitochondrial medicine company, has reported that the last of a total of 972 patients have now been enrolled and treated in its ongoing European phase III ...
NeuroVive extends partnership agreement with InVentiv Health to prepare for upcoming market launch
Agreement expands consulting services acquired by NeuroVive, with the possibility of a broader partnership for development and commercialization services.
Supplementary subscription undertakings by transfer of subscription rights
One of NeuroVive's largest shareholders, Baulos Capital (formerly Private Placement Sprl) and Dr. Guo Weicheng, co-founder of Sihuan Pharmaceuticals (the company's partner in China) have undertaken to ...
Last day of trading in subscription rights in the ongoing rights issue
NeuroVive Pharmaceutical AB (publ) today announced that 22 January 2014 is the last day of trading in subscription rights in the company's ongoing new issue. The subscription period will continue unti ...
Report from Extraordinary General Meeting
On 13 December, NeuroVive Pharmaceutical AB (publ) held an Extraordinary General Meeting (EGM), whose resolutions are summarized in what follows. All resolutions were reached with the requisite majori ...
NeuroVive signs collaboration agreement with Isomerase Therapeutics and receives the first milestone payment from Sihuan
NeuroVive Pharmaceutical AB (publ), a leading mitochondrial medicine company, has signed a collaboration agreement with Isomerase Therapeutics to develop the molecules that were recently acquired from ...